All News

Here's a roundup of this week's coronavirus-related news.

In-depth interviews from 59 women living with HIV revealed that many women preferred long-acting injectable antiretroviral therapy for its convenience, privacy, and perceived effectiveness.

Officials with the FDA approved niraparib (Zejula, GlaxoSmithKline), a once-daily, oral monotherapy, for the first-line maintenance treatment of platinum-responsive advanced ovarian cancer regardless of biomarker status.

Americans are increasingly concerned about drug shortages due to the coronavirus disease 2019 (COVID-19) pandemic, according to a new survey by prescription savings service SingleCare.

The campaign will feature testimonials from patients of the COVID-19 pandemic’s “unsung heroes.”

A recent study included interviews with pharmacists in rural Kentucky counties regarding pharmacy-level barriers to opioid use disorder treatment.

One out of 7 US adults reported that they would avoid seeking health care for a fever and dry cough for fear of not being able to pay for it.

In a presidential Coronavirus Task Force briefing, NACDS affirmed the indispensable role of pharmacists during the COVID-19 pandemic.

Building literature evaluation skills is an essential teaching component during all stages of pharmacy education

The quadrivalent meningococcal vaccine is indicated persons 2 years of age and older in the United States.

Six-year data from the new analyses add evidence to the benefit-risk profile of ocrelizumab (Ocrevus, Genentech) for patients with multiple sclerosis. 

115 members of the House have come out in support of eliminating DIR fees in future coronavirus relief packages.

Famotidine, the active compound in an OTC heartburn drug, may disable a key enzyme that COVID-19 uses to replicate.

Regeneron and Sanofi will amend their ongoing trial of sarilumab (Kevzara) to enroll only “critical” hospitalized patients with COVID-19.

Depending on the situation, individuals with IBD who develop COVID-19 may want to alter their medication.

The Compounders’ Shortage Drug Source for Hospitals is now accepting shortage drug preparation information from outsourcing facilities and approved 503A compounding pharmacies.

The FDA warned against the use of hydroxychloroquine and chloroquine outside of the hospital setting or clinical trials due to safety risks. 

Here's the roundup of the latest coronavirus-related news.

To date, 19 states have authorized pharmacists to order and conduct testing for COVID-19.

The study estimates that for each child in the PICU for COVID-19, another 2381 children are infected with the virus.

Guidance includes recommendations for pharmacies providing COVID-19 testing, vaccinations.

Two new studies underscore health disparities in rural United States affecting mortality rates associated with cardiovascular disease.

Officials with the FDA have granted accelerated approval to sacituzumab govitecan-hziy (Trodelvy, Immunomedics Inc.) for previously-treated adult patients with metastatic triple-negative breast cancer.

Siponimod (Mayzent, Novartis) had a sustained effect on slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS), according to new long-term data from a phase 3 study.

The study found that genetic variability across HLA A, B, and C could affect susceptibility to and severity of COVID-19.

If health care were a country, it would be the fifth largest emitter of greenhouse gases worldwide.

This is the first diagnostic test authorized by the FDA with a home collection option for COVID-19.

The guidelines provide clinical recommendations to providers treating patients with coronavirus disease 2019 (COVID-19).

"With the introduction of this ibrutinib-rituximab combination, patients now have a more effective, non-chemoimmunotherapy option."